Proteome Sciences Share Discussion Threads

[goatherd] 01/1/2024 16:10

May I wish all posters a very prosperous New Year (happy too!)

That includes the wayward Proteome bashers, provided their prosperity comes from elsewhere and not from shorting Proteome!

[small crow] 22/12/2023 21:33

Mad Deer Disease: a warning from history

[elpirata] 22/12/2023 19:22

its that time of year again, lest we forget

freelance - 18 Dec'04 - 10:04 - 5066 of 61508


jturnbull

I concur with everything that you and others say. Got back late yesterday afternoon and spoke to Pearce who sounded extremely frustrated with the current bout of scaremongering. Just to re-inforce what you say the following points might be worth noting.

1) the company has never promised deals by the year end but 'deals could come any day'

2) They are on track to deliver as detailed in the AGM statement and re-inforced and improved on in the interims.

3) 'the market has completely underestimated the size and scope of the Proteoshop deals'

4) They are in the middle of intense negotiations on a raft of deals

5) They totally stand by their statement that they will not need further funds.

6) There are grant monies comming in the 1st quarter of next year.

7) As has been previously said, the current big pharma problems have opened up a huge opportunity for PRM which they are exploiting to the full

8) He has been traveling intensively but got back earlier in the week. All his fellow directors are traveling.

9) They are currently busier than they ever have been and will be working flat out up to Christmas eve

He also said that it is bizarre how the view from inside the company is so totally at odds with the misconceptions and rumourmongering of the outside world.

His final words to me were, ' 2005 IS GOING TO BE OUR YEAR AND WE ARE GOING TO DELIVER'

[wrighty41] 22/12/2023 17:02

Wishing all PRM long-termers a Happy Xmas.
I’m sure PRM will help 2024 be a prosperous year for all.
W41

[goatherd] 07/12/2023 17:58

Mashman,

I believe you are wrong. What is here for the investor is the vast number of biomarker patents. Proteome cannot exploit these themselves, because they do not have enough money. However, it is simply inconceivable that some of these biomarker's will not form part of some other company's repertoire.

If (when) that happens all Proteome have to do is
a. spot the use
b. demand royalties.

This will happen with stroke; and I think will happen with Alzheimer's. Both could be highly remunerative.

Proteome are still patenting, so there is plenty of patent life left.

It is all taking a lot of time, even more than I thought it would, but I sincerely believe it will come.

[mashman] 07/12/2023 17:45

Pools I just do not get how you can be so consistently bullish and yet so wrong ALL of the time. You must have wasted a good portion of your life on this simple sloth of a biotech. PRM are miles behind and need to either go bust or go private. There is nothing here for the investor.

[dominiccummings] 06/12/2023 19:04

A mere fleh wound. PRM has sailed through many worse things and still maintained its supporters (confidence)!!!

VBR
A Goatherd

[peverill] 06/12/2023 17:30

2p coming,call the debt in,take the lot for SFA.

[colinhy] 05/12/2023 17:30

pools2

The reality is that the mass spec market for labeling reagents (TMT) is declining as the example below shows that in Alzheimer's research the DDA (TMT) market is moving to DIA (label free) and subsequently Proteome Sciences revenues from their current labeling reagents will decline. This decline could be reversed when Proteome Sciences have developed and brought to market higher TMT plexing

================================================

August 2023 Next-generation proteomics technologies in Alzheimer’s disease: from clinical research to routine diagnostics

5. Conclusion
Most studies are based on the TMT technique, but lately, following the technological advances in LC-MS instrumentation, label-free proteomics is increasingly applied in clinical studies.

6. Expert opinion
On the discovery level, the design of larger exploratory studies, made possible, e.g. by increased TMT multiplexing, can raise confidence in the identified candidate biomarkers.

[pools2] 04/12/2023 23:05

Proteome Sciences (PRM) have got all bases covered here.

For every article promoting the merits of DIA analysis, you'll find at least the same amount promoting the merits of DDA analysis.

That is why Proteome Sciences are releasing their new 6-plex (isotopic) reagents for plex-DIA and new 32-plex TMT (isobaric) reagents for TMT-DDA analysis.

Proteome Sciences allows their contract services customers to choose how they want their samples analysed, either by TMT-DDA or plex-DIA methods.

[gnnmartin] 04/12/2023 21:25

Thanks for posting that, colinhy.

[monte1] 04/12/2023 19:00

What a bummer eh?

Just after being stood up as a ‘strong buy’ by that wasjobber cove n’all.

[jeffian] 04/12/2023 18:56

There go the Toll Booths then?

[jeffian] 01/12/2023 10:40

"why not show that commitment by loading up at these bargain prices."

Surely the Directors and their associates already have enough? What would be the point of buying a token amount more? They already effectively control the company.

[gemstar2] 01/12/2023 09:49

What’s the cash position here?

[peverill] 01/12/2023 08:46

Go back over many years and everything there is a glimmer of hope,CJP pulls the rug,makes you wonder what his agenda is.??

[james japp] 01/12/2023 08:30

Oh dear. Although entirely predictable (and was), natch.

[the bull] 30/11/2023 23:55

Just like the Dingleberry's do. 100% agreed, some show of faith from management. I invested in all about £100K here which is not worth that now.

[peverill] 30/11/2023 17:02

They all want voting out,might wake CJP up a bit.

[wasjobber] 30/11/2023 12:32

Agreed, there is significant value in their IP portfolio and revenue will dwarf their current level. It's not just Alzheimers Disease and Stroke, they also have an interesting position with their Cancer IP.